2024 Volume 41 Issue 3 Pages 442-446
Galcanezumab is effective for suppression of migraine in real–world clinical practice. In this study, changes in treatment response rate, side effects, and number of preventive medications were examined in 35 patients with migraine who were treated with galcanezumab at our hospital. The 50% response rates for reduction of monthly migraine days after 1 month of treatment were 64.7% in patients with episodic migraine and 22.2% in those with chronic migraine. Side effects occurred in 4 cases (11.4%) and none were serious. Galcanezumab showed effective suppression of migraine attacks from the early stages of treatment, and this effect was more pronounced in patients with episodic migraine than in those with chronic migraine. These results suggest that galcanezumab may be useful for preventing progression to chronic migraine through appropriate use in patients with episodic migraine.
